Geneva — The Global Fund to Fight AIDS, Tuberculosis and Malaria today named Daniel Camus, a highly-respected financial executive known for his expertise in strategic planning and his track record in achieving steady growth, to be its new Chief Financial Officer.
Mr. Camus has more than 25 years of experience as a senior executive, implementing long-term expansion in complex financial operations, including a recent position as Group Executive Director of Electricité de France (EDF), where he also oversaw international operations at the largest electric utility company in the world.
Mr. Camus is well-known among financial leaders in Europe for his deep knowledge of international finance, his personal integrity and his ability as a top-line manager. He holds a PhD in Finance and Economics from the Sorbonne in Paris.
"Daniel is a keystone of our transformation," said Gabriel Jaramillo, General Manager of the Global Fund. "He brings rock-solid financial expertise, private-sector perspective and unparalleled strategic thinking to the Global Fund. We are thrilled to have him join us."
Simon Bland, Chair of the Board of the Global Fund, added: "This appointment marks a major step forward for the Global Fund, as we build superior financial management into both our day-to-day operations and our long-term strategic planning."
Mr. Camus, 60, has achieved a distinguished career in finance. A graduate of the Institut d'Etudes Politiques de Paris specializing in finance, he began his career at Hoechst, a leading company of the chemical industry in Germany. Initially, he covered the financing of all affiliates of the Hoechst Group in Africa. Excelling in strategic planning and development, he was later sent to Montreal to realize the integration of a major acquisition in North America.
Over two decades, Mr. Camus developed and honed his expertise in solving complex financial challenges and steering global transformation through mergers in the health care industry. He first returned to France to join Roussel Uclaf, a pharmaceutical company, where he was soon promoted to Chief Financial Officer. He orchestrated a complex financial restructuring of Roussel in 1997, and re-built the company's financial control system, becoming General Manager in the process.
Mr. Camus was promoted to head Finance for the pharmaceutical company of Hoechst, the only Frenchman in senior management ranks of a German company. As CFO of Aventis Pharma, following the merger of Hoechst and Rhone-Poulenc, he led the financial structuring of pharmaceutical divisions across more than 130 affiliates.
In 2002, he became Group CFO of Electricité de France, one of the largest energy companies in the world, again leading the transformation of the company in a newly competitive environment and in its stock exchange listing.
Mr. Camus's steady and thoughtful manner accompanies a bold and disciplined approach to executing financial acquisitions, restructuring and oversight. He has consistently helped staff achieve higher performance, and mobilized his teams of employees to initiate change.
Mr. Camus has also served on numerous corporate boards.
Mr. Camus's appointment is the Global Fund's third major staff announcement in recent months. In April, Cees Klumper was named Chief Risk Officer. In May, Seth Faison was appointed to head the Communications Department.
Mr. Camus is married and has a 15-year-old daughter.
The Global Fund is a unique, public-private partnership and international financing institution dedicated to attracting and disbursing additional resources to prevent and treat HIV and AIDS, TB and malaria. This partnership between governments, civil society, the private sector and affected communities represents an innovative approach to international health financing. The Global Fund's model is based on the concepts of country ownership and performance-based funding, which means that people in countries implement their own programs based on their priorities and the Global Fund provides financing on the condition that verifiable results are achieved.
Since its creation in 2002, the Global Fund has become the main financier of programs to fight AIDS, TB and malaria, with approved funding of US$ 23 billion for more than 1,000 programs in 151 countries (as of mid-2012). To date, programs supported by the Global Fund are providing AIDS treatment for 3.6 million people, anti-tuberculosis treatment for 9.3 million people and 270 million insecticide-treated nets for the prevention of malaria. The Global Fund works in close collaboration with other bilateral and multilateral organizations to supplement existing efforts in dealing with the three diseases.